Outlook Therapeutics Reports Financial Results for Fiscal Year 2023 and Provides Corporate Update
Positive clinical data reported for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in 2023 from multiple clinical trials, including statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial for wet age-related macular degeneration (wet AMD) Recent financing activities…